Troels Yndigegn
Overview
Explore the profile of Troels Yndigegn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
614
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gotberg M, Berntorp K, Jeremias A, Yndigegn T, von Koch S, Linder R, et al.
JACC Cardiovasc Interv
. 2025 Feb;
18(4):455-467.
PMID: 40010917
Background: Long-term data on safety and efficacy of instantaneous wave-free ratio (IFR) vs fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) is lacking. Objectives: This study sought to...
2.
Mars K, Hofmann R, Jonsson M, Manouras A, Engvall J, Yndigegn T, et al.
Eur Heart J Cardiovasc Imaging
. 2025 Jan;
PMID: 39813147
Aims: The REDUCE-AMI trial showed that beta-blockers in patients with preserved left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) had no effect on mortality or cardiovascular outcomes. The...
3.
Berntorp K, Mohammad M, Koul S, Yndigegn T, Bergman S, Zwackman S, et al.
Int J Cardiol
. 2024 Nov;
419:132726.
PMID: 39537104
Background: Intravascular ultrasound (IVUS) guides deferral decision-making regarding the left main coronary artery (LMCA) and improves outcomes. Further studies regarding coronary physiology to guide revascularization in the LMCA are needed....
4.
Zhong B, King B, Waziri H, Yndigegn T, Engelbertsen D, Bjorkbacka H, et al.
J Transl Med
. 2024 Nov;
22(1):1011.
PMID: 39523332
Introduction: The role of the complement inhibitory proteins CD46 and CD59 in the immune response to an acute coronary syndrome (ACS) is unknown. We investigated the relationships between the shedding...
5.
Leissner P, Mars K, Humphries S, Karlstrom P, Yndigegn T, Jernberg T, et al.
Eur Heart J Acute Cardiovasc Care
. 2024 Oct;
13(11):789-797.
PMID: 39422765
Aims: Among patients with myocardial infarction (MI) with preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI trial did not demonstrate a benefit of beta-blocker vs. no beta-blocker treatment on all-cause...
6.
Yndigegn T, Gu T, Grufman H, Erlinge D, Mokhtari A, Ekelund U, et al.
ESC Heart Fail
. 2024 Sep;
11(6):4325-4334.
PMID: 39219224
Aims: Carbohydrate antigen 125 (CA125), a mucin produced by serosal cells in response to mechanical and inflammatory stimuli, has emerged as an important biomarker to guide risk stratification in heart...
7.
Mars K, Humphries S, Leissner P, Jonsson M, Karlstrom P, Lauermann J, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(8):708-718.
PMID: 39217445
Aims: In the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardial infarction (AMI) with preserved left ventricular...
8.
Yndigegn T, Koul S, Rylance R, Berntorp K, Mohammad M, Omerovic E, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
2(5):101046.
PMID: 39132394
Background: Deferral of coronary revascularization is safe whether guided by instantaneous wave-free ratio (iFR) or by fractional flow reserve (FFR). We aimed to assess long-term outcomes in patients deferred from...
9.
Pagonis C, Sandstedt M, Dworeck C, Erlinge D, Fagman E, Adlam D, et al.
JACC Cardiovasc Imaging
. 2024 Jul;
17(10):1252-1254.
PMID: 38970596
No abstract available.
10.
Yndigegn T, Hofmann R, Jernberg T
N Engl J Med
. 2024 Jul;
391(1):95.
PMID: 38959490
No abstract available.